ALGETA REPORTS INTERIM DATA FOR PROSTATE CANCER DRUG

Algeta will soon announce clinical data from a Phase II trial of its lead product Alpharadin (Radium-223). Alpharadin is a novel bone-seeking radiopharmaceutical currently in trials as a potential new treatment for bone metastases in prostate cancer patients.

The trial was initiated to study the therapeutic efficacy of Alpharadin in hormone-refractory prostate cancer patients with painful skeletal metastases using biomarkers and clinical endpoints as outcome measures.